Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke
Open accessThe DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Abstract
Stroke remains one of the most common causes of death and disability worldwide. Several preclinical studies demonstrated that the brain can be effectively protected against ischaemic stroke by two seemingly distinct treatments: remote ischaemic conditioning (RIC), involving cycles of ischaemia/reperfusion applied to a peripheral organ or tissue, or by systemic administration of glucagon-like-peptide-1 (GLP-1) receptor (GLP-1R) agonists. The mechanisms underlying RIC- and GLP-1-induced neuroprotection are not completely understood. In this study, we tested the hypothesis that GLP-1 mediates neuroprotection induced by RIC and investigated the effect of GLP-1R activation on cerebral blood vessels, as a potential mechanism of GLP-1-induced protection against ischaemic stroke. A rat model of ischaemic stroke (90 min of middle cerebral artery occlusion followed by 24-h reperfusion) was used. RIC was induced by 4 cycles of 5 min left hind limb ischaemia interleaved with 5-min reperfusion periods. RIC markedly (by ~ 80%) reduced the cerebral infarct size and improved the neurological score. The neuroprotection established by RIC was abolished by systemic blockade of GLP-1R with a specific antagonist Exendin(9–39). In the cerebral cortex of GLP-1R reporter mice, ~ 70% of cortical arterioles displayed GLP-1R expression. In acute brain slices of the rat cerebral cortex, activation of GLP-1R with an agonist Exendin-4 had a strong dilatory effect on cortical arterioles and effectively reversed arteriolar constrictions induced by metabolite lactate or oxygen and glucose deprivation, as an ex vivo model of ischaemic stroke. In anaesthetised rats, Exendin-4 induced lasting increases in brain tissue PO 2, indicative of increased cerebral blood flow. These results demonstrate that neuroprotection against ischaemic stroke established by remote ischaemic conditioning is mediated by a mechanism involving GLP-1R signalling. Potent dilatory effect of GLP-1R activation on cortical arterioles suggests that the neuroprotection in this model is mediated via modulation of cerebral blood flow and improved brain perfusion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1RAs may also offer neuroprotection by improving/maintaining CBF in the regions surrounding the affected brain area [69].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [69]
In the citing paper
“In a recent in vivo/ex vivo study using a rat model of ischemic stroke induced by MCAO, systemic administration of exendin-4 was found to be neuroprotective via its vasodilatory action on cortical arterioles and improved CBF [69].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Johnson, C. O., Nguyen, M., Roth, G. A., Nichols, E., Alam, T., Abate, D., Abd-Allah, F., Abdelalim, A., Abraha, H. N., Abu-Rmeileh, N. M., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30034-1 · Cited by 3,264
A molecular atlas of cell types and zonation in the brain vasculature
Vanlandewijck, M., He, L., Mäe, M. A., Andrae, J., Ando, K., Del Gaudio, F., Nahar, K., Lebouvier, T., Laviña, B., Gouveia, L., et al. (2018) · Nature · doi:10.1038/nature25739 · Cited by 1,892 · cited 1×
“These data are fully consistent with the results of single-cell RNA sequencing of brain vasculature [80].”
ResultGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“in the gut and also by the groups of specialized CNS neurons located in the brainstem [35, 66].”
BackgroundSelf-citationLactate in the brain: from metabolic end-product to signalling molecule
Magistretti, P. J., & Allaman, I. (2018) · Nature Reviews Neuroscience · doi:10.1038/nrn.2018.19 · Cited by 1,298 · cited 2×
“Lactate was used as a constricting agent because the release of this metabolite markedly increases in hypoxic and ischaemic conditions [43, 44, 57].”
MethodMyocardial ischaemia–reperfusion injury and cardioprotection in perspective
Heusch, G. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0403-y · Cited by 1,234 · cited 1×
“This well-characterized phenomenon is called remote ischaemic conditioning (RIC) [23, 31, 33, 39, 47].”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057
Evolving Therapies for Myocardial Ischemia/Reperfusion Injury
Ibáñez, B., Heusch, G., Ovize, M., & Van de Werf, F. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.032 · Cited by 1,009 · cited 1×
“This well-characterized phenomenon is called remote ischaemic conditioning (RIC) [23, 31, 33, 39, 47].”
Background
Cited by
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Trapp, S., & Brierley, D. I. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15638 · Cited by 154
Self-citationIncretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., & Edison, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01792-4 · Cited by 136
Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions
Bhalla, S., Mehan, S., Khan, A., & Rehman, M. U. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104896 · Cited by 108
Vergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01686-3 · Cited by 72
“There are currently two ongoing randomized, phase II studies (NCT02829502; NCT03287076) performed in patients with ischemic stroke to evaluate the impact of exenatide therapy on various mechanistic outcomes such as CBF velocity, endothelial function, inflammation, and post-stroke hyperglycemia.”
BackgroundInfluentialRen, W., Chen, J., Wang, W., Li, Q., Yin, X., Zhuang, G., Zhou, H., & Zeng, W. (2024) · Neuron · doi:10.1016/j.neuron.2023.12.012 · Cited by 68
Yang, X., Qiang, Q., Li, N., Feng, P., Wei, W., & Hölscher, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.844697 · Cited by 58
“(104) Exendin-4/ tMCAO 90 Rat 20/10min before reperfusion; i.”
BackgroundGao, J., Yao, M., Zhang, W., Yang, B., Yuan, G., Liu, J., & Zhang, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113479 · Cited by 60
GLP-1 programs the neurovascular landscape
Chen, B., Yu, X., HORVATH-DIANO, C., Ortuño, M. J., Tschöp, M. H., Jastreboff, A. M., & Schneeberger, M. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.09.003 · Cited by 62
SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
Rolek, B., Haber, M., Gajewska, M., Rogula, S., Pietrasik, A., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10080322 · Cited by 77
“Studies on animals have found that GLP-1-R agonists may increase cerebral blood flow in mice with middle cerebral artery occlusion and, therefore, improve outcomes [50].”
BackgroundLee, J.-H., You, H.-J., Lee, T.-Y., & Kang, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095234 · Cited by 55
“Hind limb blood flow occlusion and reperfusion via the release of cuff inflation was carried out for four five-minute consecutive cycles [82,89].”
MethodBell, R., Васильевна, Б. М., Bøtker, H. E., Kalkhoran, S. B., Carr, R. D., Cunningham, J., Davidson, S. M., England, T. J., Giesz, S., Ghosh, A. K., et al. (2022) · Basic Research in Cardiology · doi:10.1007/s00395-022-00947-2 · Cited by 54
“3 kDa Glucagon-like peptide-1 (GLP-1) [4, 72] and the 18 kDa immunoregulatory glycoprotein, interleukin-1α, interleukin-10, Stromal-derived factor 1a, and nitrite [13, 22, 80] (reviewed in [57, 90]).”
Self-citationSmith, C., Patterson-Cross, R., Woodward, O., Lewis, J., Chiarugi, D., Merkle, F., Gribble, F., Reimann, F., & Adriaenssens, A. (2022) · Appetite · doi:10.1016/j.appet.2022.106022 · Cited by 47
Self-citationObesity pharmacotherapy: incretin action in the central nervous system
Boer, G. A., Hay, D. L., & Tups, A. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.11.001 · Cited by 51
Boshchenko, A. A., Маслов, Л. Н., Mukhomedzyanov, А. V., Zhuravleva, O. A., Сергеевна, С. А., Naryzhnaya, N. V., Zinoveva, A., & Ilinykh, P. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094900 · Cited by 46
Stefanou, M.-I., Palaiodimou, L., Theodorou, A., Safouris, A., Fischer, U., Kelly, P. J., Dawson, J., Katan, M., Katsanos, A. H., Lambadiari, V., et al. (2024) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864241281903 · Cited by 36
“47 Given the limited number of outcome events in the present meta-analysis (326 cumulative stroke events) and the limited follow-up, type II errors cannot be excluded and larger well-designed RCTs with adequate sample sizes and trial periods are warranted to evaluate GLP-1 RAs and GIP/GLP-1 RAs…”
BackgroundKan, X., Yan, Z., Wang, F., Tao, X., Xue, T., Chen, Z., Wang, Z., & Chen, G. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14240 · Cited by 33
Abnormal brain oxygen homeostasis in an animal model of liver disease
Hadjihambi, A., Cudalbu, C., Pierzchała, K., Simičić, D., Donnelly, C., Konstantinou, C., Davies, N. A., Habtesion, A., Gourine, A. V., Jalan, R., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100509 · Cited by 29
“pO2 was monitored using optical fluorescence technology that allows real-time detection of pO2 in vivo (OxyliteTM, Oxford Optronics), as previously described.(31,32) Following the insertion of the sensor, the craniotomy was sealed from the air with petroleum jelly, preventing diffusion of ambient oxygen.”
MethodSelf-citationGuan, Y., Gu, Y., Shao, H., Ma, W., Li, G., Guo, M., Shao, Q., Li, Y., Liu, Y., Wang, C., et al. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231185507 · Cited by 53
“Because capillary diameters ranged from 4 to 10 l m, 31,32 we focused our statistical analyses on vessel diameters in this range.”
Luan, S., Cheng, W., Wang, C., Gong, J., & Zhou, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1047883 · Cited by 25
Sun, H., Hao, Y., Liu, H., & Gao, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1525623 · Cited by 49
Elbadawy, N. N., Saad, M. A., Elfarrash, S., Ahmed, M. A. E., & Abdelkader, N. F. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177305 · Cited by 29
Steven, S., Kuntić, M., Münzel, T. F., & Daiber, A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100082 · Cited by 26
“270 Meta-analyses of CVOTs confirm the overall CV safety of GLP-1RA, with significant reductions in all-cause mortality.”
The potential mechanism and clinical application value of remote ischemic conditioning in stroke
Zhu, Y., Li, X., Lei, X., Tang, L., Wen, D., Zeng, B., Zhang, X., Huang, Z., & Guo, Z. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01800 · Cited by 25
“Nizari et al. (2021) and Zhang et al. (2012) both discovered that RIPC can reduce the range of cerebral infarction in IS models.”
InfluentialLiraglutide Ameliorates Cerebral Ischemia in Mice via Antipyroptotic Pathways
Yang, L., Cheng, J., Shi, G., Zhang, C., Du, Y., Chen, L., Qiao, H., Chen, R., & Zhang, X. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03574-4 · Cited by 18
“Lg has a large number of functions, including antiapoptotic [41, 42], anti-inflammatory, antioxidative [9, 43], and antitumor [44] effects and the ability to promote vascular regeneration [45], dilate cerebral arterioles [46], and limit harmful increases in the levels of free radicals [47–49].”
BackgroundChen, Y., Wang, L., Zhou, Y., Wang, Y., Qin, W., Wang, M., Liu, B., Tian, Q., Xu, H., Shen, H., et al. (2025) · Basic Research in Cardiology · doi:10.1007/s00395-025-01096-y · Cited by 18
“A recent study demonstrated that these agents dilate cerebral arterioles, enhance blood flow, and mediate remote neuroprotection against ischemic stroke [24].”
InfluentialKról, M., Kupnicka, P., Żychowska, J., Kapczuk, P., Szućko-Kociuba, I., Prajwos, E., & Chlubek, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146777 · Cited by 19
“In the vascular system, GLP-1R is found in SMCs of ventricular blood vessels and tibial and thoracic arteries in mice [21] as well as in the cerebrovascular system, including cortical arterioles, capillaries, and venules [27].”
Human Glucose Transporters in Health and Selected Neurodegenerative Diseases
Szablewski, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157392 · Cited by 21
Li, J., Cheng, J., Zhang, W., Lan, L., & Ge, W. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108362 · Cited by 24
Zeng, J., Hu, K., Wang, Z., Huang, Y.-C., Zhang, Y., Peng, H., & Ma, S. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00086 · Cited by 20
Williams, D. M., Atkinson, M., & Evans, M. (2023) · Stroke · doi:10.1161/strokeaha.122.042109 · Cited by 18
Ma, J., Liu, Y., Hu, J., Liu, X., Yin, X., Xia, W., Shen, Z., Kong, X., Wu, X., Mao, L., et al. (2024) · Endocrine · doi:10.1007/s12020-024-04013-w · Cited by 20
Tu, X.-K., Chen, P., Chen, J., Ding, Y.-H., Chen, Q., & Shi, S. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109603 · Cited by 14
Lü, M., Wang, Y., Yin, X., Li, Y., & Li, H. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.905400 · Cited by 13
“Several potential mechanisms of action also explain the cerebroprotective effects of RIPostC, and studies have shown that RIPostC may mediate neuroprotection through glucagon-like-peptide-1 receptor (GLP-1R) activation (38) and may also exert cerebroprotective effects by mediating the release of extracellular vesicles…”
BackgroundFrom diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists
Dave, B. P., Chorawala, M. R., Shah, I., Shah, N. N., Bhagat, S. U., Prajapati, B. G., & Thakkar, P. C. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09793-y · Cited by 17
“…findings show that a pathway involving GLP-1R signaling mediates the neuroprotection against ischemic stroke created by distant s ho w e d no i n c r ea s e i n a dv e r s e e v e n t s i n T 2 D p a ti e n t s p r on e t o i m p a i r e d r e n a l f un c ti on [ 136 ] ischemia training [157].”
Michaelsen, M. K., Drasbek, K. R., Valentin, J. B., Svart, M. V., Larsen, J. B., Kruuse, C. R., Simonsen, C. Z., & Blauenfeldt, R. A. (2025) · Stroke · doi:10.1161/strokeaha.125.053075 · Cited by 15
Shi, L., Jiang, C., Xu, H., Wu, J., Lu, J.-J., He, Y., Yin, X., Chen, Z., Cao, D., Shen, X., et al. (2023) · Pharmaceutical Biology · doi:10.1080/13880209.2023.2228379 · Cited by 12
“Previous studies have demonstrated that vasodilation responses contribute to increased brain blood flow, promote cerebral collateral recruitment, and reduce infarct size during ischaemic stroke (Gregori-Pla et al. 2019; Nizari et al. 2021).”
BackgroundQin, L., Tong, F., Li, S., & Ren, C. (2024) · Biomolecules · doi:10.3390/biom14111408 · Cited by 11
Glucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart
Krieger, J., Daniels, D., Lee, S. J., Mastitskaya, S., & Langhans, W. (2024) · Comprehensive physiology · doi:10.1002/cph4.7 · Cited by 15
“The GLP-1Rs expressed in arteriolar smooth muscle cells play a key role in brain GLP-1R signaling effects on cerebrovascular tone, through GLP- 1R-induced vasodilation of cortical arterioles mediated by a cAMP-dependent pathway (Nizari et al. 2021) (Figure 10E).”
InfluentialEndogenous Vasoactive Peptides and Vascular Aging‐Related Diseases
Chen, Y., Qi, Y., & Lu, W. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1534470 · Cited by 13
“…blood fl ow by a cAMP/PKA signaling pathway (3) Upregulated the expression of antiaging factors including p-AMPK α , PPAR-γ , PGC-1 α , and SIRT1 [138, 139, 134] 13 Oxidative Medicine and Cellular Longevity HN also attenuated microvascular remodeling, in fl am-mation, and apoptosis in ApoE-/-…”
Stroke in the Patient With Type 2 Diabetes
Jerkins, T. W., & Bell, D. S. H. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.01.010 · Cited by 11
Asif, M., Asif, A., Rahman, U. A., Farooqi, H. A., Fatima, O., Ali, W., Jafar, U., & Amin, M. H. J. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70059 · Cited by 13
Mastitskaya, S., Freitas, F., Evans, L., & Attwell, D. (2026) · Nature Communications · doi:10.1038/s41467-026-69555-1 · Cited by 9
“The increase in coronary blood fl ow that we suggest here is produced by GLP-1 and has similarities to the increase in cerebral blood fl ow suggested to result from GLP-1 release during remote ischaemic preconditioning evoked before stroke 63 .”
Targeting Metabolic Dysregulation in Alzheimer’s Disease: A Potential Therapeutic Strategy
Barnwal, N., Dubey, S., & Tiwari, P. K. (2025) · Current Drug Metabolism · doi:10.2174/0113892002408089250912080734 · Cited by 190
Effects of remote ischemic conditioning on cognitive performance: A systematic review
Amorim, S., Felicio, A. C., Aagaard, P., Suetta, C., Blauenfeldt, R. A., & Andersen, G. (2022) · Physiology & Behavior · doi:10.1016/j.physbeh.2022.113893 · Cited by 8
Wang, S., Liu, A., Xu, C., Hou, J., & Hong, J. K. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09244-8 · Cited by 9
“Recent studies have revealed that glucagon-like peptide-1 (GLP-1) exerts significant neuroprotective effects in a wide variety of central nervous system diseases, including ischaemic stroke and neurodegenerative disorders [14–16].”
BackgroundThe role of hypoxia/ischemia preconditioning in ischemic stroke
Zhu, L., Su, G., Li, R., Ma, T., Chen, W., Song, J., Wu, Q., An, Y., Wang, C., & Zhang, Z. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.01.042 · Cited by 9
The role of preconditioning in the development of resilience: Mechanistic insights
Holcombe, J., & Weavers, H. (2022) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2022.02.011 · Cited by 9
Steiner, A., Owen, B. M., Bauer, J. P., Seanez, L., Kwon, S., Biddinger, J. E., Huffman, R., Ayala, J. E., Nobis, W. P., & Lewis, A. S. (2022) · Hippocampus · doi:10.1002/hipo.23469 · Cited by 8
“Finally, strong expression of tdTomato was found throughout the brain in blood vessels, consistent with known localization of GLP-1R in brain arteriolar smooth muscle and endothelial cells (Nizari et al., 2021).”
BackgroundWang, H., Ko, H., Leung, T. W. H., Huang, J., Sai, J., Liang, Y., Li, H., Zhang, J., Cao, Q., Zang, W., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66167-z · Cited by 7
“…promotion of M2 microglia polarization 14 , reduction of neuronal apoptosis and promotion of neurogenesis 15 , whereas indirect effects include amelioration of BBB breakdown 16 , stabilization of blood glucose, modulation of systemic in fl ammation 6 , and mimicking of ischemic preconditioning 17 .”
Zou, G., Yu, R., Zhao, D., Duan, Z., Guo, S., Wang, T., Ma, L., Yuan, Z., & Yu, C. (2023) · Journal of Natural Medicines · doi:10.1007/s11418-023-01759-x · Cited by 4
Xu, F., Liu, T., Liu, H., Deng, J., He, S., Lu, Z., Zhang, H., & Dong, H. (2025) · Perioperative Medicine · doi:10.1186/s13741-025-00497-w · Cited by 4
Raised intracranial pressure alters cortical vascular function and cephalic allodynia
Grech, O., Rubio‐Beltrán, E., Stanyer, E. C., Labastida‐Ramírez, A., Lavery, G. G., Hill, L. J., Holland, P. R., & Sinclair, A. J. (2025) · Brain · doi:10.1093/brain/awae415 · Cited by 4
“46 Of interest, the GLP-1R agonist exenatide has been shown to increase tissue oxygenation in rodent models, indicating additional potentially beneficial effects of the drug in the CNS. 47”
He, Y., Wang, L., Cao, T., Jiao, S., Chen, H., Lin, C., Guo, Q., He, F., & Cai, H. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117091 · Cited by 4
GLP-1 Receptor Agonists: Beyond Diabetes—What the Neurosurgeon Needs to Know
Abdulrazeq, H., Taman, M., Ali, R., Doberstein, C., Sullivan, P. Z., Sampath, P., Telfeian, A. E., Gokaslan, Z. L., Fridley, J., & Asaad, W. F. (2024) · Neurosurgery Open · doi:10.1227/neuprac.0000000000000098 · Cited by 7
Quiróz-González, S., López-Espinosa, E., Segura‐Alegría, B., Rodríguez‐Torres, E. E., & Jiménez‐Estrada, I. (2024) · The European Physical Journal Special Topics · doi:10.1140/epjs/s11734-024-01427-5 · Cited by 3
Chen, H. A., McIntyre, M. K., Kakadiya, J., Rai, P., Essibayi, M. A., Salim, H. A., Azzam, A. Y., Latifikhereshky, S., Yedavalli, V. S., Altschul, D., et al. (2026) · Stroke · doi:10.1161/strokeaha.126.055692 · Cited by 3
Lee, Y. K., Chang, Y. Y., Jang, H. N., Ma, D. J., & Song, H. B. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119635 · Cited by 2
Song, T., Wang, B., Li, Y., Zhao, Y., Li, J., Wang, Y., & Li, X. (2025) · Mediators of Inflammation · doi:10.1155/mi/8217035 · Cited by 2
“Moreover, stimulation of GLP-1R may widen cerebral arteries, increase blood fl ow, reduce infarct volume, and ameliorate neurological de fi cit symptoms produced by ischemic stroke [28], which implies that GLP-1R agonists have neurotrophic and neuroprotective effects in nervous sys-tem disease [30].”
Yaghmayee, S., Moazzeni, A. S., Jamialahmadi, T., Karav, S., Yaribeygi, H., Kesharwani, P., & Sahebkar, A. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.06.009 · Cited by 2
Research Progress of Perioperative Application of GLP-1 and Its Protective Effects on Organs
Hong, X., Pang, Z., Liu, Y., Xue, L., Jian-dong, H., & Yang, W. (2023) · Journal of Clinical and Nursing Research · doi:10.26689/jcnr.v7i4.5033 · Cited by 1
“GLP-1RAs like exenatide can effectively reverse the constriction of cortical arterioles induced by metabolites lactate or hypoxia and glucose deficiency, promote the continuous increase of PO2 in brain tissue, regulate cerebral blood flow and improve cerebral perfusion, and protect the nerves of ischemic stroke ([49]).”
BackgroundTargeting ER Stress of GLP-1 Receptor Agonist in Diabetic Retinopathy
Huang, H., Wang, Y., Gao, S., Li, N., Zhong, Y., & Shen, X. P. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117623 · Cited by 2
Zhang, X., An, J., Guo, X., Li, J., & Wang, R. (2026) · Biomolecules · doi:10.3390/biom16040568 · Cited by 1
“In preclinical animal models, RIC has been shown to limit infarct size [7–10], improve neurological function scores [11,12], and preserve mitochondrial function [13,14].”
Arterial responses to infusion of glucagon-like peptide-1 in humans: A randomized trial study
Ghanizada, H., Christensen, R. H., Al‐Karagholi, M. A., Elbahi, F. A., Coskun, H., & Ashina, M. (2022) · Peptides · doi:10.1016/j.peptides.2022.170736 · Cited by 1
Neuroprotective potential of incretinomimetics
Kokin, A. S., Суплотова, Л. А., Сергеевна, Д. Т., & Makarova, O. B. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-159
The Neurologic Effects of Those Popular Weight Loss Drugs Come Into Focus
Hurley, D. (2024) · Neurology Today · doi:10.1097/01.nt.0001007264.08516.74
AVC, nouveaux traitements : place des agonistes du récepteur du GLP-1
Vergès, B. L. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.07.005
Introduction to Prehabilitation
Watson, A., & Barr, K. P. (2024) · Springer eBooks · doi:10.1007/978-3-031-72862-4_1
Mastitskaya, S., de Freitas, F. S. S., Evans, L., & Attwell, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.26.661857
Enni, J. B. A., & Kloner, R. A. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.09.022
Zhang, B., Kong, L., Wang, Y., He, W., Yang, M., Zhang, X., Chen, X., Zhang, Y., Liu, B., Bai, M., et al. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00990
Kamarova, M., Alhashimi, A., Aziz, M., Balami, J. S., Buck, A., McGinnis, M., Majid, A., Ali, A., & Baig, S. S. (2026) · NeuroSci · doi:10.3390/neurosci7020040
Negida, Y., Khand, Y., Hawas, Y., Yadav, V., Mohamed, K. M. H., & Saha, R. K. (2026) · medRxiv · doi:10.64898/2026.04.29.26352109
GLP-1 agonist and neuroprotection in Stroke and Parkinson’s disease: A systematic review
Parekh, D. S., Kudaiarov, D., Inban, P., Agrawal, A., Prajjwal, P., & Tariq, H. (2026) · Disease-a-Month · doi:10.1016/j.disamonth.2026.102151
Brunelli, N., Altamura, C., Marcosano, M., Vico, C., Bach-Pages, M., d’Onofrio, L., Rossi, S. S., Costa, C. M., Sacco, S., Silvestrini, M., et al. (2026) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2026.100558
Brucar, L. R., Miller, K. M., & Volkow, N. D. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106990
Alsharif, M., Shrebaty, O., Aloudah, M. A., Alqahtani, M., AlOubili, R. S., Ahmed, M. J., AlBani, B., & Bana, A. E. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1969490 · Cited by 1
Metadata
- Authors
- Nizari, S., Basalay, M., Chapman, P., Korte, N., Korsak, A., Christie, I. N., Theparambil, S. M., Davidson, S. M., Reimann, F., Trapp, S., Yellon, D. M., & Gourine, A. V.
- Affiliations
- University College London (GB)
- University of Cambridge (GB)
- Corresponding author
- Gourine, Alexander V.
- ORCID
- Venue
- Basic Research in Cardiology
- Published
- 2021-05-03
- Volume
- 116
- Issue
- 1
- Pages
- 32-32
- ISSN
- 0003-9217 (ISSN-L)
- 0300-8428
- 1435-1803
- PMC
- PMC8093159
- OpenAlex
- W3159867433
- Cited by
- 77
- References
- 91
- Citations by year
- 2026: 11 · 2025: 21 · 2024: 15 · 2023: 9 · 2022: 20 · 2021: 1
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Basic Research in Cardiology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Lancaster EPrints (Lancaster University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Apollo
- Apollo (cc-by)
- Funders
- Wellcome Trust (200893)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Keywords
- GLP-1 receptor, remote ischemic conditioning, ischemic stroke, neuroprotection, cerebral blood flow, cerebral arterioles, vasodilation, exendin-4, exendin-9-39, middle cerebral artery occlusion, oxygen-glucose deprivation, cerebral oxygenation, GLP-1 receptor agonists
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Ischemic Stroke, Animals, Arterioles, Cerebrovascular Circulation, Disease Models, Animal, Hindlimb, Male, Peptide Fragments, Regional Blood Flow, Vasodilation, Vasodilator Agents, Rats, Sprague-Dawley, Neuroprotective Agents, Ischemic Preconditioning, Infarction, Middle Cerebral Artery, Rats, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.